Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Calcipotriol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment A | EXPERIMENTAL | Eligible subjects will receive 0.1 percent pazopanib ointment. |
| Subjects receiving treatment B | EXPERIMENTAL | Eligible subjects will receive 0.5 percent pazopanib ointment. |
| Subjects receiving treatment C | EXPERIMENTAL | Eligible subjects will receive 1 percent pazopanib ointment. |
| Subjects receiving treatment D | PLACEBO_COMPARATOR | Eligible subjects will receive pazopanib vehicle as negative control. |
| Subjects receiving treatment E | PLACEBO_COMPARATOR | Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control. |
| Subjects receiving treatment F | PLACEBO_COMPARATOR | Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control. |
| Name | Type | Description |
|---|---|---|
| Pazopanib | DRUG | Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent. |
| Pazopanib vehicle | DRUG | Pazopanib vehicle will be given to subjects. |
| Betamethasone valerate | DRUG | Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects. |
| Calcipotriol | DRUG | Calcipotriol ointment with 0.005 percent concentration will be given to subjects. |
Inclusion criteria: * Stable (2-3 months) chronic plaque psoriasis covering greater than 5% body surface area (as determined by PASI palm method). * Other than having chronic plaque psoriasis, subject is health and ambulatory. * Women will be eligible to enter the study if they are of non-child-bea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 9 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 13 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-001, ORKA-002 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 3 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
Calcipotriol is a small molecule being developed by GSK plc under the ticker GSK for psoriasis, a dermatology condition. It is in Phase 1 clinical development. The compound is also catalogued under the ChEMBL identifier CHEMBL2109562.
Calcipotriol is being studied for the treatment of psoriasis, specifically chronic plaque psoriasis. The single registered trial enrolled adults aged 18 years and older with the condition. It is investigational and has not been established as a marketed treatment for psoriasis.
Calcipotriol targets PTHLH and acts as an inhibitor of that target. This mechanism underlies its development as a small molecule therapeutic for psoriasis. The target class is inhibitor, and the drug is not biomarker selected in the trial conducted to date.
GSK plc, which trades under the ticker GSK, is the developer of calcipotriol. The company is responsible for the clinical program in psoriasis, a dermatology indication. The asset is a small molecule in Phase 1 development.
Calcipotriol is in Phase 1 clinical development. It is investigational and is not approved for marketing. One Phase 1 trial has been completed, and no active trials are currently listed for the program.
Calcipotriol has been evaluated in one completed Phase 1 trial, NCT00358384, titled Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034. The trial enrolled 10 participants in France, was randomized and placebo controlled, and included adults aged 18 years and older of all sexes.